Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study to Evaluate the Efficacy and Safety of RPT193 as Monotherapy in Adults With Moderate-to-Severe Atopic Dermatitis

NCT05399368 is registered in ClinicalTrials.gov with RAPT Therapeutics, Inc. as lead sponsor.

NCT NCT05399368
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05399368 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study to Evaluate the Efficacy and Safety of RPT193 as Monotherapy in Adults With Moderate-to-Severe Atopic Dermatitis
Lead sponsor
RAPT Therapeutics, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
June 7, 2022
Completion date
May 24, 2024
Enrollment
229 (actual)
Sites
59

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis